Coronavirus: Kiwi scientist behind leading Covid-19 treatment
Coronavirus: Kiwi scientist behind leading Covid-19 treatment
Current Time 1:24
Duration 3:23
This story was originally published on RNZ.co.nz and is republished with permission.
A New Zealand scientist has created the compound which is now a front runner as a treatment option for Covid-19.
Meanwhile, a group of scientists has asked the government for funding,
so when an anti-viral treatment drug becomes available, New Zealand can
manufacture it here.
Without a vaccine or complete global eradication – a life without Covid-19 feels like a distant dream.
READ MORE:
* Coronavirus: Full coverage
* Rest home staff on edge
* Bridges' leadership questioned
* OIA suspension call rebuffed
* Nurse Jenny's 'banter' with PM
* Coronavirus: Full coverage
* Rest home staff on edge
* Bridges' leadership questioned
* OIA suspension call rebuffed
* Nurse Jenny's 'banter' with PM
But scientists believed anti-virals would be useful in treating Covid-19.
The drugs could reduce the amount of time a person is infectious, the
severity of that infection, and ideally keep people out of the hospital
system.
Eventually, the drugs could be used preventatively, and offered to
frontline health and rest care workers to prevent them from contracting
the virus.
The Ferrier Research Institute's director, Professor Richard Furneaux,
said one anti-viral drug that looked promising in the treatment of
Covid-19 was designed and synthesised by his colleague Professor Peter
Tyler.
"It was part of a partnered intellectual property licence to a company
called BioCryst Pharmaceuticals in the US, [it] was discovered by them
to be a potent anti-viral compound.
"It is now called Galidesivir," Furneaux said.
It had been trialled and proven effective in cats with a type of coronavirus, a variation of the human virus.
It was moving to the next phase, of human trials in Brazil.
This is one of the trials Furneaux and a group of colleagues would be monitoring for success.
The group was made up of medicinal chemists, clinicians and
virologists, including infectious diseases specialist from Otago
University Dr Kurt Krause.
"What our group proposes to do is to monitor the science, rank the
science that is the best in terms of identifying the compounds that look
to us to be the most effective and most likely to help the most people
who have serious Covid-19 infection," he said.
Dr Krause said once a successful anti-viral was found, it would be
patented by a big pharmaceutical company and New Zealand would have to
purchase it off them.
He said the biggest issue was the potential to be locked out of the market as every country in the world tried to buy it.
"It's very likely those companies would say 'we are unable to supply
anything to you now, we could in several years from now, or down the
road but right now we are just swamped'.
"And that's where what we are saying, look what we could do is actually
partner with you guys and make those medicines here in New Zealand."
He said there was a possibility they would not get permission from the
big companies, but with the government authority they could go ahead
anyway.
A chemical patents specialist at A J Park, Duncan de Geest said this
would be an unlikely scenario – but there are provisions that would
protect New Zealand if it needed to happen.
"There are Crown use provisions in the patents act that permit the
Crown to either use themselves, or authorise another person to use a
patented invention without that being an infringement," he said.
"They are not commonly invoked and their are quite stringent
restrictions about how they can be invoked. They are intended to allowed
the crown to respond to, for example the Civil Defence emergencies."
Comments
Post a Comment